In 2013, Bristol-Myers Squibb pivoted on its research and development plans. Discovery in metabolics, neuroscience and virology was out; immuno-oncology and specialty diseases were in. Given the sky-high expectations for the first of the immuno-oncology successes — BMS's checkpoint inhibitors ipilimumab and nivolumab — Francis Cuss, Chief Scientific Officer of BMS, stands behind these decisions. He talks with Asher Mullard about the reasons for the company's strategy rethink, the challenges of changing tack and his hopes for immuno-oncology, fibrosis and genetically defined diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Francis Cuss. Nat Rev Drug Discov 14, 672–673 (2015). https://doi.org/10.1038/nrd4748
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4748
